Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447078 · ClinicalTrials.gov registry record · Phase 3
Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection
A Phase 3 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
NCT05447078 is a Phase 3 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 492 participants.
The verdict
NCT05447078, a Phase 3 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
Study Summary
This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Immulina TM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05447078
The ClinicalTrials.gov registry entry for NCT05447078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 492 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05447078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05447078 about?
NCT05447078 is a clinical study titled "Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection". This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.
What is the current status of trial NCT05447078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2022-07-01. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT05447078?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Immulina TM (DRUG).
Who is sponsoring clinical trial NCT05447078?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.